Moderna used its Science Day event to unveil new research and early development progress, highlighting an expanding push beyond vaccines into oncology, rare diseases, and next-generation cell therapies.

 

"As we execute our strategic plan to become a diversified, multi-modality biotechnology company, we are preparing to manage three commercial franchises, Infectious Disease Vaccines, Intismeran, and Rare Disease Therapeutics, while advancing a broad mRNA pipeline and continuing to invest in research and development," said Stéphane Bancel, CEO of Moderna. 

 

"Working across three strategic horizons, we are applying our mRNA platform expertise to validate, scale and expand our modalities, with new modalities in the clinic, including T-cell engagers, and new modalities soon to be in the clinic, like in vivo CAR-T," added Bancel.

  

The company said it is executing a dual-track strategy: driving near-term commercial growth from approved products—Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX—while simultaneously accelerating a deeper late-stage and early-stage pipeline across infectious diseases, oncology, and rare genetic conditions.

 

At the center of Moderna’s long-term plan is its “three horizons” framework. Horizon 1 includes its approved and late-stage products. Horizon 2 focuses on emerging clinical programs, primarily in oncology and multiple sclerosis. Horizon 3 targets future modalities expected to enter human trials by the end of 2027, including in vivo CAR-T therapies designed to reprogram immune cells directly inside the body.

 

The company’s Research and Early Development unit (mRED) is driving this next wave of innovation, advancing platform-enabled therapies toward clinical proof-of-concept while expanding what mRNA technology can do beyond vaccines.

 

Moderna also highlighted its “Scientific Intelligence Engine,” which integrates internal and external data with artificial intelligence, machine learning, automation, and robotics. The system is designed to accelerate discovery and continuously improve development decisions through a feedback loop of real-world and experimental data.

 

On the platform side, Moderna emphasized that its mRNA system is built on three pillars—mRNA science, delivery science, and manufacturing processes—allowing it to generate repeatable modalities that can be scaled across disease areas.